Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1481 - Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced Non-Small-Cell Lung Cancer (NSCLC) patients (pts) with squamous (sq) histological type.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Cytotoxic Therapy

Tumour Site

Presenters

Francesco Grossi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

F. Grossi1, P. Jaskiewicz2, E. Pichon3, G. Czyzewicz4, D.M. Kowalski5, L. Ciuffreda6, R. Garcia Gomez7, S. Caruso8, J. Bosch Barrera9, C. Ta Thanh Minh10, S. Gautier11, H. Hervieu12, S. Henriet10, G. De Castro Jr.13

Author affiliations

  • 1 Oncology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 2 Oncology, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 3 -, CHRU Bretonneau, 37044 - Tours/FR
  • 4 Test Esmo, Szpital Specjalistyczny im. Jana Pawla II, 31-202 - Krakow/PL
  • 5 Oncology Department, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 6 Oncology Department, AOU S. Giovanni Battista - Molinette, 10126 - Torino/IT
  • 7 Oncology Department, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 8 Var, CH de la Dracénie-Draguignan, 83300 - Draguignan/FR
  • 9 Oncology Department, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, 17007 - Girona/ES
  • 10 Medical Affairs Oncology, Pierre Fabre Oncologie France, 92100 - Boulogne-Billancourt/FR
  • 11 Biometry Department, IRPF, Pierre Fabre, Toulouse/FR
  • 12 -, Pierre Fabre, 92100 - Boulogne-Billancourt/FR
  • 13 Clinical Oncology, ICESP - Instituto do Câncer do Estado de São Paulo, 01426-030 - Sao Paulo/BR
More

Resources

Abstract 1481

Background

The doublets OV+P and GEM+P are among standard treatment options in NSCLC. The study aims to assess efficacy, safety of OV+P (Arm A) and GEM+P (Arm B), followed by maintenance with OV or GEM respectively.

Methods

Pts were randomised to receive (every 3-week cycles): OV at 80 mg/m² D1 and D8 (60 mg/m² Cycle 1) + P 80 mg/m² D1 or GEM 1250 mg/m² (D1 and D8) + P 75 mg/m² D1. After 4 cycles of combination, pts without progressive disease received single agent OV or GEM respectively as maintenance until progression or unacceptable toxicity. Primary endpoint: Disease Control Rate (DCR) on study treatment period (combination, maintenance). Secondary endpoints: safety, efficacy, quality of life.

Results

113 pts were included between 2013-2015 in intent-to-treat population (ITT). Baseline: 57 pts (Arm A)/ 56 pts (Arm B), median age of 61 and 64.5 years, stage IV 96.5% and 91.1% respectively. In Arm A/ B, 57 pts and 56 were treated in combination period; in maintenance, 29 and 28 pts were treated with OV or Gem. Final results (ITT) for study treatment period in Arm A/ B: DCR 73.7% [95%, CI (62.4; 100.0)] and 75% [95%, CI (63.7; 100.0)]. Median duration of treatment 12.1 and 13.2 weeks; objective response 24.6% [14.1; 37.8] and 30.4% [18.8; 44.1]; median [95% CI] duration of disease control in months (mo) 4.8 [4.1-5.7] and 5.2 [4.3-6.6]; median PFS: 4.2 (2.8-4.9) and 4.3 (3.1-5.5) mo; median survival: 10.2 (6.9-12.9) and 8.4 (5.3-11.9) mo. Total of any grades (Gr) of related adverse events (r-AEs) arm A/ B respectively: 87.7% and 92.9%. Any grade of related infections: 1.8% vs 8.9%.Gr 3-4 of selected r-AEs: nausea/vomiting 1.8%/3.5% vs 8.9%/ 5.4%, peripheral neuropathy 0% vs1.8%, renal failure 1.8% vs 3.6%, septic shock 0 vs 1.8%. Grade 1-2 related alopecia (8.8% vs 21.4%). One toxic death in each arm. Biological toxicities of gr 3-4 neutropenia 43.9%/37.5%, anaemia 17.5%/10.7%, thrombocytopenia 1.8%/10.7%. Full results to be presented at the meeting.

Conclusions

This study confirms efficacy, safety of OV+P in sq NSCLC with a trend for a better median survival for OV+P.

Clinical trial identification

EUDRACT NUMBER: 2012-003531-40.

Legal entity responsible for the study

Pierre Fabre Médicament.

Funding

Pierre Fabre Médicament.

Editorial Acknowledgement

We thank all caregivers, investigators, nurses, data manager for their active participation and involvement in this study.

Disclosure

F. Grossi: Consulting, advisory role: Pierre Fabre, BMS, MSD, Roche. E. Pichon: Consulting, advisory role: BMS, AstraZeneca; Travel/accomodation, expenses: Astrazeneca, BMS. G. Czyzewicz: Honoraria: Roche, BMS, AstraZeneca; Consulting, advisory board: AstraZeneca, BMS, MSD, Roche; Research funding: BMS, Roche, AstraZeneca, Pierre Fabre Medicament; Expert testimony, Astrazeneca; Travel/accomodation: AstraZeneca, Roche, Pfizer. J. Bosch Barrera: Consulting, advisory boards: Pierre Fabre, BMS, Roche, AstraZeneca, Boehringer Ingelheim. C. Ta Thanh Minh: Employment pharmaceutical industry (PFM); Other ownership interest; Research project (PFM); Travel/accommodation. S. Gautier, H. Hervieu, S. Henriet: Employment, stocker/other ownership, research funding: Pierre Fabre. G. De Castro Jr.: Consulting or advisory role: Teva, Pfizer, Bayer, Roche, MSD; Speakers' bureau: AstraZeneca, Bayer, Novartis, Roche, MSD, BMS, Merck; Travels expenses: MSD, Novartis, Pfizer, AstraZeneca, Roche; Boehringer Ingelheim; Honoraria: AstraZeneca, Pfizer, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.